文献速递肿瘤 PET/CT放射性药物与辐射防护

使用长轴视野PET/CT扫描仪进行全身[18F]DPA-714动力学评估

Whole-Body [18F]DPA-714 Kinetic Assessment Using PET/CT Scanner with Long Axial Field of View.
PubMed 文献 · J Nucl Med · 2025-07-01

本研究纳入39名来自前瞻性VeCosCO研究的COVID后参与者,行全身动态[18F]DPA-714 PET/CT扫描(注射后0-60分钟),以确定不同脑外器官的最佳药代动力学模型。结果显示骨和骨骼肌首选不可逆单组织室模型,肾和肺首选可逆双组织室模型,其他器官首选可逆单组织室模型;心肌分布容积最高(33.27 ± 11.91 mL·cm-3),肺最低(5.12 ± 2.85 mL·cm-3);骨流入速率高于骨骼肌(0.101 vs. 0.052 mL·cm-3·min-1,P < 0.001)。

要点

  • 骨和骨骼肌首选不可逆单组织室模型,肾和肺首选可逆双组织室模型,其他器官首选可逆单组织室模型。
  • 心肌平均分布容积最高(33.27 ± 11.91 mL·cm-3),肺最低(5.12 ± 2.85 mL·cm-3)。
  • 骨平均流入速率高于骨骼肌(0.101 vs. 0.052 mL·cm-3·min-1,P < 0.001)。

核心结论

  • TSPO受体广泛分布于全身,[18F]DPA-714在多个器官摄取很高;骨和骨骼肌首选不可逆模型、其他器官首选可逆模型来描述[18F]DPA-714动力学;未来用[18F]DPA-714评估脑外炎症的研究应考虑TSPO丰富器官间的这些动力学差异。

研究设计与样本

  • 从前瞻性VeCosCO研究纳入39名对TSPO具有高亲和力结合、伴或不伴持续主诉的COVID后参与者。
  • 行全身动态[18F]DPA-714 PET/CT扫描(注射后0-60分钟)。
  • 以升主动脉为基础的图像衍生输入函数经手动动脉血样校正,建立代谢校正血浆输入函数。
  • 从肾上腺、骨、肾、肝、肺、心肌、胰腺、骨骼肌、脾和甲状腺的感兴趣体积得出时间-活性曲线。
  • 对时间-活性曲线非线性回归拟合含额外血容量参数的1组织和2组织室模型来研究[18F]DPA-714动力学。

主要发现

  • 骨和骨骼肌首选不可逆单组织室模型。
  • 肾和肺首选可逆双组织室模型。
  • 其他器官首选可逆单组织室模型。
  • 10个脑外器官显示不同程度的[18F]DPA-714摄取,心肌平均分布容积最高(33.27 ± 11.91 mL·cm-3),肺最低(5.12 ± 2.85 mL·cm-3)。
  • 骨平均流入速率高于骨骼肌(0.101 vs. 0.052 mL·cm-3·min-1,P < 0.001)。

临床怎么用

  • 作者认为,未来使用[18F]DPA-714评估脑外炎症的研究应考虑TSPO丰富器官间的这些动力学差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multisystemic inflammation might be a key pathophysiologic mechanism in post-coronavirus disease 2019 (post-COVID) syndrome. N,N-diethyl-2-(2-(4-(2-fluoroethoxy)phenyl)5,7dimethylpyrazolo[1,5a] pyrimidin-3-yl)acetamide ([18F]DPA-714), which binds with high affinity the translocator protein (TSPO) receptor, is used as a marker of inflammation. Therefore, quantifying [18F]DPA-714 uptake throughout the body could assess extracerebral inflammation in post-COVID syndrome. However, the pharmacokinetics of whole-body [18F]DPA-714 uptake have not yet been assessed. Thus, before quantifying whole-body [18F]DPA-714 uptake in post-COVID syndrome, the aim of this study was to identify the optimal pharmacokinetic model in different extracerebral organs. Methods: Thirty-nine post-COVID participants with high-affinity binding for TSPO with or without persistent complaints were enrolled from the prospective VeCosCO study. Whole-body dynamic [18F]DPA-714 PET/CT scans (0-60 min after injection) were performed. Ascending aorta-based image-derived input functions were corrected with manual arterial blood samples to establish metabolite-corrected plasma input functions. Time-activity curves were derived from volumes of interest in the adrenal gland, bone, kidney, liver, lung, myocardium, pancreas, skeletal muscle, spleen, and thyroid. [18F]DPA-714 kinetics were studied by nonlinear regression fitting of 1- and 2-tissue-compartment models with an additional blood volume parameter to the time-activity curves. Results: An irreversible single-tissue-compartment model was preferred in bone and skeletal muscle, a reversible 2-tissue-compartment model was preferred in kidney and lung, and a reversible single-tissue-compartment model was preferred in the other organs. Our results showed various levels of [18F]DPA-714 uptake in the 10 extracerebral organs. The highest mean volume of distribution was found in myocardium (33.27 ± 11.91 mL⋅cm-3), and the lowest mean volume of distribution was found in lung (5.12 ± 2.85 mL⋅cm-3). The mean influx rate was higher in bone than in skeletal muscle (respectively, 0.101 vs. 0.052 mL⋅cm-3⋅min-1; P < 0.001). Conclusion: The TSPO receptor is widely distributed over the entire body, with very high [18F]DPA-714 uptake in several organs. An irreversible model in bone and skeletal muscle and a reversible model in the other organs were preferred to describe [18F]DPA-714 kinetics. Further studies using [18F]DPA-714 to assess extracerebral inflammation should consider these kinetic differences among TSPO-rich organs.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Palard-Novello X, Visser D, Yaqub M, et al. Whole-Body [18F]DPA-714 Kinetic Assessment Using PET/CT Scanner with Long Axial Field of View. J Nucl Med. 2025. PMID: 40441893. doi:10.2967/jnumed.124.268979

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。